Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Change in Account Payables (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Change in Account Payables for 16 consecutive years, with $469711.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 328.73% to $469711.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $586326.0, a 163.6% increase, with the full-year FY2025 number at $9835.0, down 96.23% from a year prior.
  • Change in Account Payables was $469711.0 for Q4 2025 at PharmaCyte Biotech, up from $66005.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $589849.0 in Q3 2023 to a low of -$591967.0 in Q4 2023.
  • A 5-year average of $34446.8 and a median of $32524.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 5525.14% in 2022; the steepest drop was 6606.06% in 2022.
  • PharmaCyte Biotech's Change in Account Payables stood at -$8703.0 in 2021, then skyrocketed by 3572.95% to $302251.0 in 2022, then plummeted by 295.85% to -$591967.0 in 2023, then skyrocketed by 65.31% to -$205357.0 in 2024, then skyrocketed by 328.73% to $469711.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Change in Account Payables are $469711.0 (Q4 2025), $66005.0 (Q3 2025), and -$85743.0 (Q2 2025).